5 Strategies For APAC Drug Submissions: Korea, China, Japan

Korea, China, and Japan are no strangers to clinical trials in Asia. They have large patient populations and sophisticated regulatory systems and infrastructure, and each has worked to adopt the CTD or eCTD for submissions. That said, they also require the most content to be presented in-language to local regulators. So how do you manage up to five million words of critical content translation across 330 files and submit on time?

In July, TransPerfect presented at Bio Asia-Taiwan’s One-on-One Partnering” event, where the hot topic facing Taiwan’s booming biotech industry was “How can we get our drugs registered in China quickly?” Continue reading to learn more from Alicja Borek (Senior Director, Asia), Wei Du (Director, China Strategy), and Silas Chen (Account Management, Taiwan) as they presented a five-point plan to enable smoother submissions.